Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(18):1329; doi:10.1093/jnci/dji328
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hayasaka, E.
Right arrow Articles by Zielinski, S. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hayasaka, E.
Right arrow Articles by Zielinski, S. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

In Brief

Elana Hayasaka, Sarah L. Zielinski

The first 10% of the full text of this article appears below.

Varying Prevalence of HPV Types May Affect Effectiveness of Vaccine

The proportion of women who are infected with the high-risk human papillomavirus (HPV) types HPV16 and HPV18, for which vaccines are currently in development, varies by geographic region, which may make the vaccines more effective in Europe than in other parts of the world, according to a new study published online August 16 by The Lancet.

The prevalence of HPV infections, which cause cervical cancer, . . . [Full Text of this Article]

Aspirin and Other NSAIDs May Be Associated With Lower Risk of Colorectal Cancer

Results of Phase I Oncology Studies Underreported


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?